Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, England, United Kingdom.
MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, England, United Kingdom.
Mol Cancer Res. 2021 May;19(5):753-756. doi: 10.1158/1541-7786.MCR-20-0871. Epub 2021 Jan 26.
Despite strong biological rationale for the use of type-I IFNs for the treatment of acute myeloid leukemia (AML), their usage is limited to few hematologic malignancies. Here, we propose that innate immune sensing machinery, particularly the stimulator of IFN genes pathway, may be exploited to deliver antileukemic effects in AML.
尽管 I 型干扰素(IFNs)在治疗急性髓系白血病(AML)方面具有强有力的生物学理论基础,但它们的应用仅限于少数血液恶性肿瘤。在这里,我们提出先天免疫感应机制,特别是干扰素基因刺激途径,可用于在 AML 中发挥抗白血病作用。